文献速递糖尿病

通过交叉轮换四种不同药物类别优化糖尿病白蛋白尿降低治疗:一项随机交叉试验

Optimization of Albuminuria-Lowering Treatment in Diabetes by Crossover Rotation to Four Different Drug Classes: A Randomized Crossover Trial.
PubMed 文献 · Diabetes Care · 2023-01-01

该随机交叉试验纳入26例1型糖尿病和37例2型糖尿病伴白蛋白尿患者,随机顺序接受替米沙坦80mg、恩格列净10mg、利格列汀5mg和巴瑞替尼2mg各4周,间隔4周洗脱。个体最佳药物使UACR首次和确认暴露分别平均降低39.6%和22.4%,而其他三种药物平均变化+1.6%。作者认为数据支持系统轮换不同药物类别以克服RAS抑制治疗抵抗。

要点

  • 个体最佳降UACR药物差异大:替米沙坦对33例(52%)最佳,恩格列净和利格列汀各11例(17%),巴瑞替尼8例(13%)。
  • 最佳药物首次暴露UACR平均降39.6%(95%CI -44.8至-33.8;P<0.001),确认暴露降22.4%(95%CI -29.7至-12.5;P<0.001)。
  • 其他三种药物UACR平均变化+1.6%(95%CI -4.3%至8.0%;P=0.593 vs 基线),与确认期最佳药物差异30.9%(95%CI 18.0至45.3;P<0.001)。

核心结论

  • 参与者对不同降UACR药物类别的反应存在大且可重复的变异,数据支持系统轮换不同药物类别以克服RAS抑制治疗抵抗。

研究设计与样本

  • 随机交叉试验,纳入26例1型糖尿病和37例2型糖尿病患者,UACR 30-500 mg/g且eGFR>45 mL/min/1.73 m2,随机顺序接受4周替米沙坦80mg、恩格列净10mg、利格列汀5mg和巴瑞替尼2mg,间隔4周洗脱,随后再次暴露于个体UACR降低最大的药物4周。

主要发现

  • 最佳药物个体差异大:替米沙坦对33例(52%)最佳,恩格列净和利格列汀各11例(17%),巴瑞替尼8例(13%)。
  • 个体最佳药物首次暴露使UACR平均降低39.6%(95%CI -44.8至-33.8;P<0.001),确认暴露平均降低22.4%(95%CI -29.7至-12.5;P<0.001),首次与确认暴露Pearson相关系数0.39(P=0.017)。
  • 其他三种药物UACR平均变化+1.6%(95%CI -4.3%至8.0%;P=0.593 vs 基线),与确认期个体最佳药物差异30.9%(95%CI 18.0至45.3;P<0.001)。

临床怎么用

  • 作者认为数据支持系统轮换不同药物类别以克服RAS抑制治疗抵抗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Renin-angiotensin system (RAS) inhibitors decrease the urinary albumin to creatinine ratio (UACR) but are ineffective in up to 40% of patients. We hypothesized that rotation through different drug classes overcomes RAS inhibitor resistance and tested this in a randomized crossover trial. RESEARCH DESIGN AND METHODS: We assigned 26 adults with type 1 diabetes and 37 with type 2 diabetes and UACR between 30 and 500 mg/g and estimated glomerular filtration rate >45 mL/min/1.73 m2 to 4-week treatment periods with telmisartan 80 mg, empagliflozin 10 mg, linagliptin 5 mg, and baricitinib 2 mg in random order, separated by 4-week washout periods. Each participant was then re-exposed for 4 weeks to the drug that induced that individual's largest UACR reduction. Primary outcome was the difference in UACR response to the best-performing drug during the confirmation period versus UACR response to the other three drugs. RESULTS: There was substantial variation in the best-performing drug. Telmisartan was best performing for 33 participants (52%), empagliflozin and linagliptin in 11 (17%), and baricitinib in 8 participants (13%). The individuals' best-performing drug changed UACR from baseline during the first and confirmatory exposures by a mean of -39.6% (95% CI -44.8, -33.8; P < 0.001) and -22.4% (95% CI -29.7, -12.5; P < 0.001), respectively. The Pearson correlation for first versus confirmatory exposure was 0.39 (P = 0.017). The mean change in UACR with the other three drugs was +1.6% (95% CI -4.3%, 8.0%; P = 0.593 versus baseline; difference versus individuals' best-performing drug at confirmation, 30.9% [95% CI 18.0, 45.3]; P < 0.001). CONCLUSIONS: We demonstrated a large and reproducible variation in participants' responses to different UACR-lowering drug classes. These data support systematic rotation through different drug classes to overcome therapy resistance to RAS inhibition.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Curovic VR, Jongs N, Kroonen MYAM, et al. Optimization of Albuminuria-Lowering Treatment in Diabetes by Crossover Rotation to Four Different Drug Classes: A Randomized Crossover Trial. Diabetes Care. 2023. PMID: 36657986. doi:10.2337/dc22-1699

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。